• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation.

作者信息

Boros L, Chuang C, Butler F O, Bennett J M

出版信息

Cancer. 1985 Nov 1;56(9):2161-9. doi: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m.

DOI:10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m
PMID:3902204
Abstract

Every adult acute nonlymphocytic leukemia patient in Rochester, New York seen from January 1975 to January 1982 was studied. Fifty percent of the patients did not receive combination chemotherapy. Among those who did, there was a significant selection bias toward placing patients with better prognostic features on protocol. Protocol patients were also treated with higher doses of chemotherapy than nonprotocol patients. However, these factors did not completely explain the significantly better complete response (CR) rate and survival among protocol patients. Eastern Cooperative Oncology Group (ECOG) participation remained an independent variable associated with a better outcome. An improvement in CR rate was seen during the 7-year period studied as compared to that seen between 1965 and 1974. The study provided evidence that the availability and use of ECOG protocols was a positive factor in the improvement of leukemia treatment in Rochester.

摘要

相似文献

1
Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation.
Cancer. 1985 Nov 1;56(9):2161-9. doi: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m.
2
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.
J Clin Oncol. 1984 Aug;2(8):865-70. doi: 10.1200/JCO.1984.2.8.865.
3
Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy.
Cancer. 2002 Sep 1;95(5):1064-70. doi: 10.1002/cncr.10805.
4
Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Cancer Treat Rep. 1987 Feb;71(2):137-40.
5
Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.强化缓解后治疗强度可改善急性髓系白血病的预后:东部肿瘤协作组(ECOG)的经验。东部肿瘤协作组
Leukemia. 1992;6 Suppl 2:116-9.
6
Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.维持化疗可延长成人急性非淋巴细胞白血病的缓解期。
J Clin Oncol. 1988 Apr;6(4):583-7. doi: 10.1200/JCO.1988.6.4.583.
7
Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience.
Cancer. 1997 Dec 1;80(11 Suppl):2205-9.
8
Treatment of acute nonlymphocytic leukemia in young and elderly patients.年轻及老年患者急性非淋巴细胞白血病的治疗
Cancer. 1985 Dec 1;56(11):2587-92. doi: 10.1002/1097-0142(19851201)56:11<2587::aid-cncr2820561109>3.0.co;2-8.
9
Adult acute leukemia. The Rochester (NY) Experience.成人急性白血病。罗切斯特(纽约州)的经验。
Arch Intern Med. 1976 Nov;136(11):1256-61.
10
Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
Cancer Treat Rep. 1987 Feb;71(2):201-3.

引用本文的文献

1
Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study.不同亚洲乳腺癌患者参与临床试验的障碍与促进因素:一项定性研究
BMC Womens Health. 2016 Jul 22;16:43. doi: 10.1186/s12905-016-0319-1.
2
Comparison of survival outcomes among cancer patients treated in and out of clinical trials.比较临床试验内外治疗的癌症患者的生存结果。
J Natl Cancer Inst. 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13.
3
Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.
参与随机对照试验的患者与接受类似干预但未参与试验的类似患者的结局比较。
Cochrane Database Syst Rev. 2008 Jul 16;2008(3):MR000009. doi: 10.1002/14651858.MR000009.pub4.
4
Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden.瑞典214例未经挑选的急性髓系白血病患者的治疗、长期预后及预后变量
Br J Cancer. 2000 Apr;82(8):1387-92. doi: 10.1054/bjoc.1999.1123.
5
Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.根据疾病分期治疗多发性骨髓瘤:一项前瞻性随机研究,比较较温和与更积极的细胞周期抑制策略。多发性骨髓瘤研究与治疗协作组
Br J Cancer. 1994 Dec;70(6):1203-10. doi: 10.1038/bjc.1994.474.
6
The breast cancer research scandal: addressing the issues.乳腺癌研究丑闻:解决相关问题。
CMAJ. 1995 Apr 15;152(8):1195-7.
7
Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.低剂量阿糖胞苷治疗髓系白血病和骨髓增生异常综合征。
Ir J Med Sci. 1988 Jul;157(7):238-41. doi: 10.1007/BF02949309.